\n <\/p>\n
Revealed on Mar 24, 2026<\/p>\n
<\/p>\n
\n <\/p><\/blockquote>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n Comply with us on X @investorideas<\/strong><\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
Revealed on Mar 24, 2026
Share
(Investorideas.com
Newswire) a number one funding platform for retail traders experiences
breaking Medical Tech Inventory information for
Aethlon Medical, Inc.
(Nasdaq: AEMD), a medical therapeutic firm centered on creating merchandise to
deal with most cancers and life-threatening […]<\/p>\n","protected":false},"author":1,"featured_media":9041,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/www.investorideas.com\/CO\/AEMD\/news\/2026\/images\/032426-1.jpg","fifu_image_alt":"","footnotes":""},"categories":[41],"tags":[2500,4949,4951,3421,4953,73,4950,1950,221,4952],"class_list":["post-9039","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-investment","tag-advances","tag-aemd","tag-clinical","tag-cohort","tag-dsmb","tag-final","tag-oncology","tag-positive","tag-review","tag-trial"],"yoast_head":"\n
\n
\n Share
\n <\/a>
\n<\/section><\/div>\n
\n
<\/p>\n
\n
\n <\/figure>\n
\n
<\/p>\n
\n (Investorideas.com<\/a>
\n Newswire) a number one funding platform for retail traders experiences
\n breaking Medical Tech Inventory information for
\n Aethlon Medical, Inc.<\/a>
\n (Nasdaq: AEMD<\/a>), a medical therapeutic firm centered on creating merchandise to
\n deal with most cancers and life-threatening infectious illnesses.
\n <\/p>\n
\n
<\/p>\n
\n Aethlon Medical, Inc.<\/a>
\n (Nasdaq: AEMD), a clinical-stage biotechnology firm
\n creating the investigational Aethlon Hemopurifier\u00ae, an
\n extracorporeal system for oncology and different indications, at this time
\n introduced that the impartial Knowledge Security Monitoring Board (DSMB)
\n overseeing its ongoing scientific trial AEMD-2022-06 has accomplished its
\n scheduled security evaluation of the second cohort participant information and
\n beneficial advancing to the third and ultimate cohort. Additionally they
\n said that \u201cno security considerations had been famous with Hemopurifier
\n system\/process\u201d.
\n <\/p>\n
\n The trial, titled \u201cSecurity, Feasibility, and Dose-Discovering Examine
\n of Aethlon Hemopurifier in Sufferers with Stable Tumors Who Have
\n Secure or Progressive Illness Whereas on a Remedy That Contains
\n Pembrolizumab or Nivolumab,” is being performed to evaluate the
\n Hemopurifier\u2019s security, feasibility, and optimum dosing.
\n <\/p>\n
\n The DSMB\u2014comprised of impartial medical specialists in
\n nephrology and oncology\u2014reviewed information from members
\n enrolled within the second cohort, by which sufferers obtained two
\n Hemopurifier therapies over a one-week interval. Based mostly on their
\n analysis, the DSMB discovered no security considerations and confirmed that the
\n Hemopurifier continues to reveal a good security and
\n tolerability profile. So far, no severe opposed occasions (SAEs) or
\n Dose-Limiting Toxicities (DLTs) associated to the Hemopurifier system
\n or therapy have been reported.\u00a0
\n <\/p>\n
\n “The DSMB’s continued constructive advice helps the security
\n profile noticed thus far and permits us to advance into the third
\n and ultimate cohort of this research,\u201d stated Steven LaRosa, M.D,
\n Chief Medical Officer of Aethlon Medical. “We’re inspired by
\n the gathering momentum of the trial and having a ultimate information set
\n and scientific research report back to share with potential traders,
\n companions and regulatory companies\u201d.
\n <\/p>\n
\n Enrollment for Cohort 3 is now open. On this ultimate cohort,
\n members will obtain three Hemopurifier therapies over a
\n one-week interval, additional evaluating security, feasibility, and dosing
\n parameters on the research\u2019s three lively scientific websites in
\n Australia. This trial is designed to enroll roughly 9 to 18
\n sufferers with stable tumors who’ve steady or progressive illness
\n whereas receiving therapy that features Pembrolizumab
\n (Keytruda\u00ae) or Nivolumab (Opdivo\u00ae).
\n <\/p>\n
\n The first endpoint of this trial is the incidence of opposed
\n occasions and clinically vital adjustments in security laboratory assessments
\n of Hemopurifier-treated sufferers. Along with security monitoring,
\n the research is designed to look at the variety of Hemopurifier
\n therapies wanted to lower the focus of extracellular
\n vesicles (EVs) and if these adjustments in EV concentrations enhance the
\n physique\u2019s personal pure capability to assault tumor cells. These
\n findings are anticipated to tell the design of a future efficacy and
\n security Premarket Approval (PMA) research required by regulatory
\n authorities.
\n <\/p>\n
\n Aethlon Medical, Inc. stays dedicated to advancing the
\n Hemopurifier to be used in oncology and can proceed to supply
\n updates because the scientific trial progresses.
\n <\/p>\n<\/p><\/div>\n
\n
<\/p>\n
\n About Aethlon Medical, Inc.<\/strong>
\n <\/h2>\n
\n Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical
\n system firm headquartered in San Diego, California. Aethlon is
\n advancing the Hemopurifier, to deal with unmet wants in oncology and
\n infectious illness, utilizing a novel platform designed to selectively
\n take away circulation pathogenic targets from biologic fluids.
\n <\/p>\n
\n For extra data, go to
\n www.AethlonMedical.com<\/a>
\n and observe the Firm on LinkedIn.
\n <\/p>\n
\n About Aethlon and the Hemopurifier\u00ae<\/strong>
\n <\/h2>\n
\n Aethlon Medical is a medical therapeutic firm centered on creating
\n the Hemopurifier, a scientific stage immunotherapeutic system which is
\n designed to fight most cancers and life-threatening viral infections and
\n to be used in organ transplantation. In human research, the Hemopurifier
\n has demonstrated the elimination of life-threatening viruses and in
\n pre-clinical research, the Hemopurifier has demonstrated the elimination of
\n dangerous EVs from organic fluids, using its proprietary
\n lectin-based expertise. This motion has potential functions in
\n most cancers, the place EVs could promote immune suppression and metastasis, and
\n in life-threatening infectious illnesses. The Hemopurifier is a U.S.
\n Meals and Drug Administration (FDA) designated Breakthrough Gadget
\n indicated for the therapy of people with superior or metastatic
\n most cancers who’re both unresponsive to or illiberal of ordinary of
\n care remedy, and with most cancers varieties by which EVs have been proven to
\n take part within the improvement or severity of the illness. The
\n Hemopurifier additionally holds an FDA Breakthrough Gadget designation and an
\n open Investigational Gadget Exemption (IDE) utility associated to the
\n therapy of life-threatening viruses that aren’t addressed with
\n permitted therapies.
\n <\/p>\n
\n Extra data may be discovered at
\n www.AethlonMedical.com<\/a>.
\n <\/p>\n
\n Ahead-Wanting Statements<\/strong>
\n <\/h2>\n
\n
\n This press launch accommodates forward-looking statements inside the
\n that means of Part 27A of the Securities Act of 1933 and Part 21E
\n of the Securities Change Act of 1934 that contain dangers and
\n uncertainties. Statements containing phrases equivalent to “could,” “consider,”
\n “anticipate,” “count on,” “intend,” “plan,” “venture,” “will,”
\n “projections,” “estimate,” “probably” or related expressions
\n represent forward-looking statements. Such forward-looking
\n statements are topic to vital dangers and uncertainties and
\n precise outcomes could differ materially from the outcomes anticipated in
\n the forward-looking statements. Dangers and uncertainties embody, however
\n are usually not restricted to, scientific trial outcomes, regulatory approvals,
\n the flexibility to acquire further financing, and market acceptance of
\n the Firm’s merchandise, as extra absolutely described within the Firm’s
\n filings with the Securities and Change Fee. These
\n forward-looking statements are primarily based upon Aethlon’s present
\n expectations and contain assumptions which will by no means materialize or
\n could show to be incorrect. All forward-looking statements contained
\n on this press launch converse solely as of the date on which they had been
\n made. Besides as could also be required by regulation, the Firm doesn’t intend,
\n nor does it undertake any obligation, to replace this data to
\n mirror future occasions or circumstances.<\/em>
\n <\/p>\n
\n Firm Contact:<\/strong>
Jim Frakes
Chief Government
\n Officer and Chief Monetary Officer
Aethlon Medical, Inc.
\n
Jfrakes@aethlonmedical.com<\/a>
\n <\/p>\n
\n Investor Contact:<\/strong>
Susan Noonan
S.A. Noonan
\n Communications, LLC
susan@sanoonan.com<\/a>
\n <\/p>\n
\n
<\/p>\n
\n Aethlon Medical Inc. (Nasdaq:AEMD) is a featured biotech inventory on
\n Investorideas.com Extra data on AEMD at Investorideas.com Go to:
\n <\/strong>
\n https:\/\/www.investorideas.com\/CO\/AEMD\/<\/a><\/strong>
\n <\/p>\n
\n Get Information Alerts on Aethlon Medical<\/a>
\n <\/p>\n
\n ![\"Biotech](\"https:\/\/www.investorideas.com\/images\/biotech_img.jpg\")
<\/p>\n
\n Get extra\u00a0<\/strong>biotech and medical tech information, articles<\/strong><\/a>, podcasts and\u00a0<\/strong>inventory directories<\/strong><\/a>
\n <\/p>\n
\n
<\/p>\n
\n About Investorideas.com – Massive Investing Concepts<\/strong>
\n <\/h3>\n
\n Investorideas.com is the go-to platform for giant investing concepts. From
\n breaking inventory information to top-rated investing podcasts, we cowl all of it
\n <\/p>\n
\n Comply with us on Fb
\n https:\/\/www.fb.com\/Investorideas<\/a><\/strong>
\n <\/p>\n
\n Comply with us on YouTube
\n https:\/\/www.youtube.com\/c\/Investorideas<\/a><\/strong>
\n <\/p>\n
\n
<\/p>\n
\n Join free inventory information alerts at
\n Investorideas.com\u00a0<\/strong>
\n <\/p>\n
\n https:\/\/www.investorideas.com\/Sources\/Publication.asp<\/a>
\n <\/p>\n
\n
\n <\/div>\n
\n Disclaimer\/Disclosure:<\/strong> Athelon Medical, Inc. (AEMD) is
\n a paid featured\u00a0medical tech<\/strong>\u00a0inventory on
\n Investor concepts\u00a0Extra disclosure<\/a>: Investorideas.com is a digital writer of third social gathering sourced information,
\n articles and fairness analysis in addition to creates unique content material,
\n together with video, interviews and articles. Unique content material created by
\n investorideas is protected by copyright legal guidelines aside from syndication
\n rights. Our website doesn’t make suggestions for purchases or sale of
\n shares, providers or merchandise. Nothing on our websites ought to be construed
\n as a proposal or solicitation to purchase or promote merchandise or securities. All
\n investing entails danger and attainable losses. This website is at present
\n compensated for information publication and distribution, social media and
\n advertising, content material creation and extra.\u00a0Extra disclosure<\/a>: Contact administration and IR of every firm immediately relating to particular
\n questions.
\n <\/p>\n\n","protected":false},"excerpt":{"rendered":"